Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors

MLA

Jennifer Frye, et al. “Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.” Molecular Imaging and Biology, vol. 18, Nov. 2015, pp. 446–53. EBSCOhost, https://doi.org/10.1007/s11307-015-0912-y.

APA

Jennifer Frye, Richard Laforest, Barry A. Siegel, Jeanne Mendell, Lauren Trull, Farrokh Dehdashti, Joel Picus, Syed Mahmood, Madhuri Desai, Yongjian Liu, A. Craig Lockhart, Michael J. Welch, & Stefanie Belanger. (2015). Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Molecular Imaging and Biology, 18, 446–453. https://doi.org/10.1007/s11307-015-0912-y

Chicago

Jennifer Frye, Richard Laforest, Barry A. Siegel, Jeanne Mendell, Lauren Trull, Farrokh Dehdashti, Joel Picus, et al. 2015. “Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.” Molecular Imaging and Biology 18 (November): 446–53. doi:10.1007/s11307-015-0912-y.